Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
Pivotal phase III study of GSK shingles candidate vaccine meets its primary endpoint
GSK announced a phase III study to assess the efficacy of HZ/su, investigational vaccine for shingles, has met its primary endpoint.
-
New European consortium formed to help further advance development of a GSK/NIH Ebola candidate vaccine
Consortium includes GSK and research partners from Oxford, Centre Hospitalier Universitaire Vaudois in Lausanne and the Bernhard-Nocht
-
GSK announces EU regulatory submission seeking extended indication for ambrisentan (Volibris®) in pulmonary arterial hypertension
GSK announced that it has filed a regulatory submission to the EMA for a variation to the Marketing Authorisation for ambrisentan(Volibris®)
-
GSK statement on Established Products Portfolio
GSK started a process to consider the divestment of certain North American and European brands in its Established Products Portfolio.
-
GSK names winners of 2014 Discovery Fast Track Challenge
GSK announced the winners of its second Discovery Fast Track Challenge for academic researchers & drug discovery scientists at GSK
-
GSK statement on first phase 1 trial results of a candidate Ebola vaccine
Results from phase 1 trial published in NEJM show that GSK/NIH Ebola candidate vaccine was well-tolerated in the 20 healthy adult volunteers
-
Regulatory update on transaction with Novartis
GSK providing AN update relating to the major three-part transaction with Novartis AG (the Original Announcement).
-
Publication of Circular and Notice of General Meeting relating to the proposed major transaction with Novartis
GSK announced a major conditional transaction with Novartis involving its Consumer Healthcare, Vaccines and Oncology businesses
-
GSK leads Access to Medicine Index 2014
The Access to Medicines Index published today has ranked GSK top for the fourth consecutive time.
-
New England Journal of Medicine publishes positive results from COMBI-v study of trametinib (Mekinist™) and dabrafenib (Tafinlar™) combination
Results published in NEJM show that treatment with trametinib (Mekinist™) & Tafinlar™ improved OS compared to vemurafenib monotherapy
-
GSK launches first call for proposals for research in to non-communicable diseases in sub-Saharan Africa
GSK launched first call for proposals for its Africa NCD Open Lab, to support much-needed scientific research into NCDs in Africa.
-
GSK announces EU regulatory submission seeking additional indication for eltrombopag (Revolade™) (1)
GSK announced submission to EMA for eltrombopag (Revolade™) for the treatment of patients with SAA who have insufficient response to IST.
-
GSK announces regulatory submissions for mepolizumab in severe eosinophilic asthma
GSK announced that it has filed regulatory submissions in the USA and Europe for mepolizumab for patients with severe eosinophilic asthma
-
Results announcement for the third quarter 2014
GSK announces Q3 core EPS of 27.9p +5% CER excluding divestments and dividend of 19 pence per share
-
GSK update on current development status of the GSK/NIH Ebola vaccine candidate
GSK is working WHO to accelerate development of our investigational Ebola vaccine and to ramp up production as quickly as possible
-
Data published on Anoro® Ellipta® demonstrate improved lung function compared to tiotropium
Respiratory Medicine has published positive results from a third lung function study comparing the efficacy and safety of Anoro® Ellipta®.
-
Stiefel, a GSK company, announces start of phase III study of subcutaneous ofatumumab for pemphigus vulgaris
Stiefel, announced phase III study to evaluate the efficacy and safety of subcutaneous ofatumumab in patients with pemphigus vulgaris
-
GSK appoints Mr Urs Rohner to its Board as a Non-Executive Director
GSK today announced the appointment of Mr Urs Rohner to its Board as a Non-Executive Director, effective 1 January 2015.
-
GSK commits further funding to advance bioelectronics research with creation of 5 million Innovation Challenge Fund
GSK announced, $5 million ICF to encourage and advance collaborative research as part of its effort to develop bioelectronic medicines.
-
GSK announces overall survival results from phase III BREAK-3 study of Tafinlar® (dabrafenib) in patients with BRAF V600E-mutant metastatic melanoma
GSK updated results for Tafinlar® from a planned analysis of the phase III BREAK-3 study in 250 patients with BRAFV600E metastatic melanoma.
